Cargando…
Comparison of long-term outcomes of stereotactic body radiotherapy (SBRT) via Helical tomotherapy for early-stage lung cancer with or without pathological proof
BACKGROUND: Stereotactic body radio therapy (SBRT) has emerged as a standard treatment option for nonsurgical candidates with early-stage non-small cell lung cancer (NSCLC). Pathological proof is sometimes difficult to obtain in patients with solitary pulmonary nodules (SPNs). We aimed to compare th...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996902/ https://www.ncbi.nlm.nih.gov/pubmed/36890550 http://dx.doi.org/10.1186/s13014-023-02229-0 |
_version_ | 1784903148628869120 |
---|---|
author | Fan, Shaonan Zhang, Qi Chen, Jingyao Chen, Gang Zhu, Jiangyi Li, Tingting Xiao, Han Du, Shisuo Zeng, Zhaochong He, Jian |
author_facet | Fan, Shaonan Zhang, Qi Chen, Jingyao Chen, Gang Zhu, Jiangyi Li, Tingting Xiao, Han Du, Shisuo Zeng, Zhaochong He, Jian |
author_sort | Fan, Shaonan |
collection | PubMed |
description | BACKGROUND: Stereotactic body radio therapy (SBRT) has emerged as a standard treatment option for nonsurgical candidates with early-stage non-small cell lung cancer (NSCLC). Pathological proof is sometimes difficult to obtain in patients with solitary pulmonary nodules (SPNs). We aimed to compare the clinical outcomes of stereotactic body radiotherapy via helical tomotherapy (HT-SBRT) for early-stage lung cancer patients with or without a pathological diagnosis. METHODS: Between June 2011 and December 2016, we treated 119 lung cancer patients with HT-SBRT, including 55 with a clinical diagnosis and 64 with a pathological diagnosis. Survival outcomes, including local control (LC), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS), were compared between two cohorts with and without a pathological diagnosis. RESULTS: The median follow-up for the whole group was 69 months. Patients with a clinical diagnosis were significantly older (p = 0.002). No significant differences were observed between the clinical and pathological diagnosis cohorts in terms of the long-term outcome, with 5-year LC, PFS, CSS, and OS of 87% versus 83% (p = 0.58), 48% versus 45% (p = 0.82), 87% versus 84% (p = 0.65), and 60% versus 63% (p = 0.79), respectively. Recurrence patterns and toxicity were also similar. CONCLUSIONS: Empiric SBRT appears to be a safe and effective treatment option in a multidisciplinary setting when patients with SPNs highly suggestive of malignancy are unable/refuse to obtain a definitive pathological diagnosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13014-023-02229-0. |
format | Online Article Text |
id | pubmed-9996902 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99969022023-03-10 Comparison of long-term outcomes of stereotactic body radiotherapy (SBRT) via Helical tomotherapy for early-stage lung cancer with or without pathological proof Fan, Shaonan Zhang, Qi Chen, Jingyao Chen, Gang Zhu, Jiangyi Li, Tingting Xiao, Han Du, Shisuo Zeng, Zhaochong He, Jian Radiat Oncol Research BACKGROUND: Stereotactic body radio therapy (SBRT) has emerged as a standard treatment option for nonsurgical candidates with early-stage non-small cell lung cancer (NSCLC). Pathological proof is sometimes difficult to obtain in patients with solitary pulmonary nodules (SPNs). We aimed to compare the clinical outcomes of stereotactic body radiotherapy via helical tomotherapy (HT-SBRT) for early-stage lung cancer patients with or without a pathological diagnosis. METHODS: Between June 2011 and December 2016, we treated 119 lung cancer patients with HT-SBRT, including 55 with a clinical diagnosis and 64 with a pathological diagnosis. Survival outcomes, including local control (LC), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS), were compared between two cohorts with and without a pathological diagnosis. RESULTS: The median follow-up for the whole group was 69 months. Patients with a clinical diagnosis were significantly older (p = 0.002). No significant differences were observed between the clinical and pathological diagnosis cohorts in terms of the long-term outcome, with 5-year LC, PFS, CSS, and OS of 87% versus 83% (p = 0.58), 48% versus 45% (p = 0.82), 87% versus 84% (p = 0.65), and 60% versus 63% (p = 0.79), respectively. Recurrence patterns and toxicity were also similar. CONCLUSIONS: Empiric SBRT appears to be a safe and effective treatment option in a multidisciplinary setting when patients with SPNs highly suggestive of malignancy are unable/refuse to obtain a definitive pathological diagnosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13014-023-02229-0. BioMed Central 2023-03-08 /pmc/articles/PMC9996902/ /pubmed/36890550 http://dx.doi.org/10.1186/s13014-023-02229-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Fan, Shaonan Zhang, Qi Chen, Jingyao Chen, Gang Zhu, Jiangyi Li, Tingting Xiao, Han Du, Shisuo Zeng, Zhaochong He, Jian Comparison of long-term outcomes of stereotactic body radiotherapy (SBRT) via Helical tomotherapy for early-stage lung cancer with or without pathological proof |
title | Comparison of long-term outcomes of stereotactic body radiotherapy (SBRT) via Helical tomotherapy for early-stage lung cancer with or without pathological proof |
title_full | Comparison of long-term outcomes of stereotactic body radiotherapy (SBRT) via Helical tomotherapy for early-stage lung cancer with or without pathological proof |
title_fullStr | Comparison of long-term outcomes of stereotactic body radiotherapy (SBRT) via Helical tomotherapy for early-stage lung cancer with or without pathological proof |
title_full_unstemmed | Comparison of long-term outcomes of stereotactic body radiotherapy (SBRT) via Helical tomotherapy for early-stage lung cancer with or without pathological proof |
title_short | Comparison of long-term outcomes of stereotactic body radiotherapy (SBRT) via Helical tomotherapy for early-stage lung cancer with or without pathological proof |
title_sort | comparison of long-term outcomes of stereotactic body radiotherapy (sbrt) via helical tomotherapy for early-stage lung cancer with or without pathological proof |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996902/ https://www.ncbi.nlm.nih.gov/pubmed/36890550 http://dx.doi.org/10.1186/s13014-023-02229-0 |
work_keys_str_mv | AT fanshaonan comparisonoflongtermoutcomesofstereotacticbodyradiotherapysbrtviahelicaltomotherapyforearlystagelungcancerwithorwithoutpathologicalproof AT zhangqi comparisonoflongtermoutcomesofstereotacticbodyradiotherapysbrtviahelicaltomotherapyforearlystagelungcancerwithorwithoutpathologicalproof AT chenjingyao comparisonoflongtermoutcomesofstereotacticbodyradiotherapysbrtviahelicaltomotherapyforearlystagelungcancerwithorwithoutpathologicalproof AT chengang comparisonoflongtermoutcomesofstereotacticbodyradiotherapysbrtviahelicaltomotherapyforearlystagelungcancerwithorwithoutpathologicalproof AT zhujiangyi comparisonoflongtermoutcomesofstereotacticbodyradiotherapysbrtviahelicaltomotherapyforearlystagelungcancerwithorwithoutpathologicalproof AT litingting comparisonoflongtermoutcomesofstereotacticbodyradiotherapysbrtviahelicaltomotherapyforearlystagelungcancerwithorwithoutpathologicalproof AT xiaohan comparisonoflongtermoutcomesofstereotacticbodyradiotherapysbrtviahelicaltomotherapyforearlystagelungcancerwithorwithoutpathologicalproof AT dushisuo comparisonoflongtermoutcomesofstereotacticbodyradiotherapysbrtviahelicaltomotherapyforearlystagelungcancerwithorwithoutpathologicalproof AT zengzhaochong comparisonoflongtermoutcomesofstereotacticbodyradiotherapysbrtviahelicaltomotherapyforearlystagelungcancerwithorwithoutpathologicalproof AT hejian comparisonoflongtermoutcomesofstereotacticbodyradiotherapysbrtviahelicaltomotherapyforearlystagelungcancerwithorwithoutpathologicalproof |